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Abstract
Fungal infections of the central nervous system (CNS) are
uncommon. Despite several advancements in diagnosis
and treatment of these infections, the mortality rates
remain high. The current retrospective study was
planned to define the demographic and clinical features
of patients with CNS fungal infections. Conducted at Aga
Khan University Hospital, Karachi, and comprising CNS
fungal infections operated between January 2000 and
December 2015. The study analysed whether a short
course of pre-operative anti-fungal therapy may improve
outcomes in these patients. There were 47 cases
confirmed on histopathology and/or microbiology.
Outcome measures used were Glasgow coma score
(GCS), Glasgow outcome score (GOS) and Karnofsky
performance score (KPS). The overall 30-day mortality
was 20(42.5%). Fungal infections of the CNS can occur in
both immune-compromised and immune-competent
patients. Early diagnosis, radical surgery, pre-operative
anti-fungal therapy for at least 2 weeks, pre- and post-
operative Voriconazole therapy results in more
favourable outcomes.
Keywords: Central nervous system, Fungal infection,
Craniotomy, Voriconazole.
Introduction
Fungal infections of the central nervous system (CNS),
initially thought to be a disease of immune-compromised
patients, are now increasingly reported in immune-
competent patients as well.1-6 The incidence appears to
be on the rise over the last few decades which may be
attributed to several factors, including improved
diagnostic evaluation, longer life expectancy of general
population, increasing prevalence of diabetes mellitus,
longer survival of immune-compromised population
including transplant recipients, wider use of
immunosuppressive drugs and increased number of
human immunodeficiency virus (HIV) infected patients,
etc.1-5,7-9 Hot and dry climate with high content of fungal
spores in agricultural dust may be responsible for the
endemic level of this infection.2,3,5
Patients may present with meningitis, meningio-
encephalitis, cerebro-vasculitis, cerebral abscesses or
granulomas.1-3,8-11 If the disease presents with mass
effect, or if there is a doubt about the diagnosis, surgery
is usually the next step in management. Surgical goals
are optimally safe resection and acquisition of tissue for
diagnostic evaluation. Some patients tend to get worse
following surgery, with several case series reporting
events such as widespread vasospasm, cerebral oedema
and acute meningio-encephalitis after surgery.2,3,12 This
has been postulated to be due to angio-invasiveness of
the organism which leads to widespread inflammatory
reactions and infarctions, consequently leading to high
morbidity and mortality.1,13,14 The case-fatality ratio of
patients with CNS fungal infections is high, which stands
especially true for CNS aspergillosis in which the
mortality for certain patient groups is reported to be as
high as 100%.1,3,8,15-20
The current study was planned to define the
demographic and clinical features of patients with CNS
fungal infections and to analyse whether a short course of
pre-operative anti-fungal therapy may improve outcomes
in these patients. 
Methods
The retrospective chart review was conducted at Aga
Khan University Hospital, Karachi, and comprised all
consecutive cases of CNS fungal infections operated
between January 2000 and December 2015. Data of all
patients who had surgery and had confirmed CNS fungal
infection on the basis of histopathology or microbiology
(staining, cultures and sensitivity), were included. Data
of patients with unconfirmed diagnosis and those
without mass effect (meningitis, thin extradural
extension of sino-nasal disease, post-operative fungal
infections) were excluded. Patients were categorised as
immune-compromised based on the presence of HIV,
chronic renal failure, chronic steroid use, diabetes
mellitus, malignancy, haematological diseases or
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tuberculosis. All other patients were categorised as
immune-competent was obtained. Since this was a
retrospective chart review, approval from the
departmental review committee (DRC). Approval from
the ethical review committee (ERC) was exempted.
Patient confidentiality was maintained at all stages.
Data was retrieved through patient files using two
databases. Our laboratory data for histopathology and
microbiology for all patients diagnosed with CNS
fungal infection and our medical records office which
classifies all cases according to the International
Classification of Disease (ICD-9). Patient demographics,
relevant clinical history, symptoms on presentation, co-
morbidities, immune status, physical examination
findings, location and pattern of lesions, radiological
imaging and impression, causative organism, pertinent
laboratory investigations, management strategies,
including both medical management by fungicidal
agents and surgical management including details of
surgery and outcome, were recorded using a self-
designed form. Outcome measures used were
mortality, Glasgow coma score (GCS), Glasgow
outcome score (GOS) and Karnofsky performance score
(KPS). These factors were noted pre-operatively, in the
immediate post-operative period, at discharge and at
each follow-up visit.
Data was analysed using SPSS v21. Mean and standard
deviation were calculated for continuous data. Frequency
and percentage were calculated for qualitative data and
predictors of mortality were assessed using Chi-
square/Fisher's exact test. P-value <0.05 was considered
statistically significant.
Results
Of the 47 patients identified, 34(72.3%) were males and
13(27.7%) females. The overall mean age was 36±18
years (range: 13-74 years). Headache was the most
common presenting symptom 38(80.9%) patients
followed by visual abnormality 19(40.4%) patients.
Vomiting, fever, seizures and neurologic weakness were
observed in 12(25.5%) patients each. The mean duration
of signs and symptoms at the time of presentation was
66.7±86.9 days (range: 2 hours to over a year). Patients
with co-morbid conditions numbered 20(42.6%).
Hypertension was present in 9(19.1%) patients, diabetes
mellitus in 6(12.8%) and chronic steroid use in 8 (17%).
Besides, 9(19.1%) patients had history of chemotherapy
or immunotherapy while chronic kidney disease was
found in 3(6.4%).
All patients underwent pre-operative magnetic
resonance imaging (MRI)of brain with and without
contrast. Most commonly involved region was the
anterior fossa and frontal lobein 16 (34%) patients and
temporal lobe in 7(14.9%) patients. Posterior cranial
fossa(infra-tentorial space) was a rarely involved
location. Cerebellar involvement was seen in 3 (6.4%)
cases and brainstem was involved in 1 (2.1%) patient
only.
A total of 39 (83%) patients were operated as elective
cases whereas emergency procedures were carried out
in the rest of the patients. Sub-total resection of fungal
mass was carried out in 15(31.9%), gross total
resection in 5(10.6%), and only a biopsy was
performed in the rest. Cerebrospinal fluid (CSF)
diversion with external ventricular drain or ventriculo-
peritoneal shunt was performed in 3(6.4%) and
2(4.3%) patients respectively. Fungal species were
successfully isolated on culture for 37(78.7%) patients
(Table-1). 
Poly-therapy was employed in 36 (76.6%) patients
while mono-therapy was initiated in the rest. All
patients received post-operative anti-fungal therapy
based on the results of fungal smear, culture,
histopathological staining or clinical impression or
suspicion of treating physicians (surgeon or infectious
diseases specialist), while 18(38.3%) patients had
received pre-operative anti-fungal therapy for a mean
duration of 18.7±58.9 days. The therapy was continued
post-operatively for a mean duration of 175±198 days.
Amphotericin B was used in 40(85.1%) patients,
Itraconazole in 30 (63.8%) and Voriconazole in
20(42.6%) patients. Patients who received pre-
operative anti-fungal therapy had significantly better
post-operative KPS compared to those who did not
receive pre-operative therapy (p=0.033). More
specifically, patients receiving pre-operative anti-
fungal for 14 days or more had a significant mortality
J Pak Med Assoc
104 G. Haider, M. S. Shamim, M. F. Khan, et al
Table-1: Frequency of each type of fungus isolated on culture.
Isolated Fungus                                                                                                   Frequency (%)
Aspergillus Flavus                                                                                                           22 (46.8)
Aspergillus Fumigatus                                                                                                     4 (8.5)
Rhizpous                                                                                                                               3 (6.4)
Fonsecaea Pedrosi                                                                                                             2 (4.3)
Aspergillus Oryzae                                                                                                             1 (2.1)
Aspergillus Terreus                                                                                                            1 (2.1)
Chaetomium species                                                                                                        1 (2.1)
Rhinocladiella Aquaspersa                                                                                              1 (2.1)
Madurella                                                                                                                             1 (2.1)
Cryptococcus                                                                                                                       1 (2.1)
Not isolated                                                                                                                      10 (21.3)
benefit (p=0.015) compared to the rest. Other
predictors associated with significant mortality benefit
and better KPS were Voriconazole therapy (p=0.007),
American Society of Anesthesiologists (ASA) level 2 or
less (p=0.016) and absence of post-operative
complications (p=0.014).
Only 16(34%) patients had an unremarkable post-
operative course while the rest had
some form of complication. A total of
22(46.8%) patients required re-
admission due to various reasons
such as breakthrough seizures or
renal impairment, and 12(25.5%)
patients required re-operation. Post-
operative neurologic, renal and
pulmonary complications occurred in
23(49.9%), 18(38.3%) and 2(4.2%)
patients respectively. Mechanical
ventilation was required in 5(10.6%)
patients. Overall 30-day mortality was
20(42.5%) patients, and reasons
included stroke, systemic fungal
infection and renal failure secondary
to amphotericin B. Mean length of
hospital stay was 13.5±10.5 days.
Among the survivors, 19(40.4%) showed improvement or
complete recovery from disease at 1-year follow-up. One
(2.12%) patient recovered from fungal pathology, but
died of some other cause (Table-2).
Discussion
A recent study described the role of radical surgery and
post-operative anti-fungal treatment for 6 weeks in
improving outcome in these patients.2 Most patients in
our study were immune-competent, young male patients,
similar to the series of Naik, et al.2 Moreover, similarity was
noted in all the baseline features and demographics
recorded in our set of patients with those from various
studies reported from South Asian, Middle-Eastern and
Sub-Saharan countries.1-4,19,21 However, the
demographics appear to have a different pattern in
reports published from Western countries.17,18,22
Clinical characteristics at presentation included fever,
headaches, seizures, hemiparesis, focal neurologic deficit,
visual abnormality and cranial nerve deficits. These
findings were similar to characteristics reported in
existing international literature.1-3,6,11,18,23,24 The duration
between presentation and beginning of signs and
symptoms showed large variations, ranging from a few
hours to weeks to even over a year. This is generally not
seen in literature. However, it is based on patient recall,
and its clinical relevance is doubtful, and any statistically
significant association between the clinical duration and
any of the outcome measures (mortality, GOS, KPS) was
not found (p>0.05). Being immuno-compromised has
been established as a predisposing factor to fungal
infection of CNS.1,3,14,16 Most of our patients did not have
co-morbidities and were immune-competent. In patients
who did have co-morbid conditions, we could not
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Table-2: Association between patient characteristics and mortality.
                                                                                                               Mortality                 p-value
                                                                                                       Yes (%)         No (%)
Prolonged Signs & Symptoms      More than 30 days     10 (50)          10 (50)          0.528
                                                                30 days or less              11 (41)          16 (59)               
Gender                                                  Male                                15 (44)          19 (56)         >0.05
                                                                Female                             6 (46)            7 (54)                 
Hemiparesis                                        Yes                                    7 (70)            3 (30)           0.086
                                                                No                                    14 (38)          23 (62)               
Co-morbid conditions                      Yes                                   11 (55)           9 (45)           0.250
                                                                No                                    10 (37)          17 (63)               
ASA Level                                             2 or less                           8 (30)           19 (70)          0.016
                                                                3 or more                       13 (65)           7 (35)                 
Re-operation                                       Yes                                    8 (67)            4 (33)           0.100
                                                                No                                    13 (37)          22 (63)               
Pre-op Anti-fungal duration         Less than 14 days       20 (54)          17 (46)          0.015
                                                                14 or more days            1 (10)            9 (90)                 
Anti-fungal poly-therapy               Yes                                   14 (39)          22 (61)          0.181
                                                                No                                      7 (64)            4 (36)                 
Itraconazole                                        Yes                                   12 (40)          18 (60)          0.319
                                                                No                                      9 (53)            8 (47)                 
Voriconazole                                       Yes                                    4 (20)           16 (80)          0.007
                                                                No                                    17 (63)          10 (37)               
Amphotericin-B                                 Yes                                   19 (48)          21 (52)          0.436
                                                                No                                      2 (29)            5 (71)                 
Post-op complication                       Yes                                   18 (58)          13 (42)          0.014
                                                                No                                      3 (19)           13 (81)               
Figure: Association of Voriconazole therapy and treatment duration of pre-operative anti-fungal with survival
percentage.
establish any significant association between having a
particular co-morbid condition and pattern of disease or
outcome. Understandably, patients who had fixed
neurological deficits such as hemiparesis at the time of
presentation were more likely to have poor post-
operative KPS (p=0.039), GOS (p=0.007) and higher
mortality (p=0.086).
Aspergillus was the most commonly isolated
causative organism.2,3,10 The frequency of
Cryptococcus in our series may be lower than
expected but that may be explained on the basis that
it is more likely to cause meningitis and commonly
affects patients with HIV infection, and there was only
one patient in our series with HIV.24 Nonetheless, no
association between the type of causative fungus and
any of the outcome measures, including mortality,
was found (p>0.05).
Since its approval by the Food and Drug
Administration (FDA), Voriconazole has become the
drug of choice for fungal infections of the CNS.6,14,17,22
Our study further supports this practice. Voriconazole
therapy was found to be strongly associated with
better survival and KPS (p<0.014) (Figure). Our study
also supports published literature that whenever
feasible, radical surgery offers better outcomes for
these patients.1-3,6,7,14,16,17,19 Patients who underwent
gross or even sub-total resection were found more
likely to have better post-operative KPS compared to
those who only had biopsy (p=0.067). As expected,
patients with ASA category 2 or less had lesser overall
mortality (p=0.016) and patients who required re-
operation for any reason were likely to have poor KPS
on post-operative follow-up (p=0.02).
Some authors have proposed that operating under cover
of anti-fungal therapy may offer better outcome.2,19,21,23,25
Our study supports this notion as patients who received
pre-operative anti-fungal therapy were likely to have
better post-operative KPS (p=0.033). More specifically,
patients receiving pre-operative anti-fungal for at least 14
days had a significant survival benefit (p=0.015). However,
we did not find a significant difference in outcome
between patients receiving anti-fungal mono-therapy
and poly-therapy. This may be because of the antagonist
effects of amphotericin-B and -azole group.21 A total of 40
patients received amphotericin-B, out of whom 18
developed renal complications (p=0.034), and 61.1% of
those who developed renal complications died because
of it (p=0.074).19
Despite advancements, fungal involvement of the
CNS remains a management challenge for the
treating physicians. Poor neurologic status at the
time of presentation, CSF involvement, decreased
immunity, and renal failure are all associated with
morbidity and poor outcome.2,3,15 In our study, the
in-hospital mortality soon after the surgery was high.
Out of 20 patients who died, 12(60%) expired during
hospital stay or within 2 weeks of surgery.19 Our
overall mortality rate was 42.5% which is similar to
the 36.4% reported by Naik et al, and 50% reported
by Sharma et al.2,9
The retrospective design of the current study is a limitation.
A larger study using more extensive multivariate analysis
may be able to reveal more information regarding the
management of CNS fungal infections.
Conclusion
Fungal infections of the CNS can occur in both immune-
compromised and immune-competent patients and a
high index of clinical suspicion is needed to detect these
infections. Early diagnosis, radical surgery, pre-operative
anti-fungal therapy for at least 2 weeks and Voriconazole
pre- and post-operation result in more favourable
outcomes. 
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